Search
Relmada Therapeutics Inc
RLMDAdd to Watchlist
6.570USD
+0.200+3.14%
Close 06/16, 16:00（ET）Quotes delayed by 15 min
687.03MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-16The current earnings forecast score of Relmada Therapeutics Inc is 8.80, ranking 54 out of 388 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
13.750
Target Price
+106.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Relmada Therapeutics Inc
RLMD
5
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Relmada Therapeutics Inc's price target?
Analysts forecast that Relmada Therapeutics Inc's price target is USD 10.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 10.00.
How have Relmada Therapeutics IncRLMD's recent earnings per share performed?
The market expectation was USD -0.22, while Relmada Therapeutics IncRLMD's earnings per share (EPS) for the previous quarter was USD -0.33. EPS for the next quarter is expected at USD -0.19.
What is the analyst rating for Relmada Therapeutics Inc?
Based on the ratings of Relmada Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
